Plasma chromogranin A: clinical implication in hormone refractory prostate cancer patients receiving docetaxel therapy

被引：0
|
作者：
Mandal, Arup K.
Sarkar, Debansu
Prasad, Rajendra
Agarwal, M. M.
Mete, U. K.
Singh, S. K.
机构：
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A140 / A140
页数：1
相关论文
共 50 条
  • [1] Plasma chromogranin A: Clinical implications in patients with castrate resistant prostate cancer receiving docetaxel chemotherapy
    Sarkar, Debansu
    Singh, S. K.
    Mandal, Arup K.
    Agarwal, Mayank M.
    Mete, Uttam K.
    Kumar, Santosh
    Mavuduru, Ravimohan S.
    Prasad, Rajendra
    [J]. CANCER BIOMARKERS, 2010, 8 (02) : 81 - 87
  • [2] CORRELATION BETWEEN PLASMA CHROMOGRANIN A LEVELS AND PROGNOSIS IN HORMONE REFRACTORY PROSTATE CANCER PATIENTS
    Mosca, Alessandra
    Berruti, Alfredo
    Tucci, Marcello
    Vana, Federica
    Bitossi, Raffaella
    Cracco, Cecilia
    Torta, Mirella
    Poggio, Massimiliano
    Scarpa, Roberto Mario
    Dogliotti, Luigi
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 38 - 39
  • [3] Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel
    Olbert, Peter Jochen
    Hegele, Axel
    Kraeuter, Petra
    Heidenreich, Axel
    Hofmann, Rainer
    Schrader, Andres Jan
    [J]. ANTI-CANCER DRUGS, 2006, 17 (08) : 993 - 996
  • [4] The predictive value of chromogranin a expression for docetaxel response in metastatic hormone refractory prostate cancer
    Gernone, A.
    Trabucco, S.
    Pagliarulo, V.
    Troccoli, G.
    Pagliarulo, A.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 100 - 100
  • [5] Prognostic role of plasma chromogranin A levels in prostate cancer patients with hormone refractory disease.
    Mosca, A
    Berruti, A
    Tucci, M
    Vana, F
    Bitossi, R
    Cracco, C
    Torta, M
    Poggio, M
    Scarpa, RM
    Dogliotti, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 850S - 850S
  • [6] Prognostic role of chromogranin A expression for docetaxel response in hormone-refractory metastatic prostate cancer
    Gernone, A.
    Trabucco, S.
    Troccoli, G.
    Pagliarulo, V.
    Pagliarulo, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Norihito Soga
    Manabu Kato
    Kouhei Nishikawa
    Yoshihiro Hasegawa
    Yasushi Yamada
    Hideaki Kise
    Kiminobu Arima
    Yoshiki Sugimura
    [J]. International Journal of Clinical Oncology, 2009, 14 : 130 - 135
  • [8] Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients
    Soga, Norihito
    Kato, Manabu
    Nishikawa, Kouhei
    Hasegawa, Yoshihiro
    Yamada, Yasushi
    Kise, Hideaki
    Arima, Kiminobu
    Sugimura, Yoshiki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (02) : 130 - 135
  • [9] Increase of circulating chromogranin a in patients with hormone-refractory prostate cancer
    不详
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [10] Circulating chromogranin A and hormone refractory prostate cancer chemotherapy
    Cabrespine, A
    Guy, L
    Gachon, F
    Curé, H
    Chollet, P
    Bay, JO
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 1347 - 1352
12345